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Abstract 
Lung cancer is a major health concern worldwide, but new immunotherapeutic 
treatments for lung cancer have shown great promise and the prognosis for many severe 
cancers including lung cancer has been improving. In May 2017, the Food and Drug 
Administration’s approved pembrolizumab, a therapeutic antibody that blocks 
lymphocytic programmed death-1 (PD-1), as a first-line treatment for any solid tumor 
with specific genetic features. Pembrolizumab is a therapeutic antibody that blocks 
lymphocytic programmed death-1 (PD-1), the ligand of which (PD-L1) is expressed on 
tumor cells and which can prevent the immune system from recognizing and destroying 
tumors. Here, we report 2 cases of double cancer (Case 1: lung and bladder cancer; Case 
2: gastric and lung cancer) in which Pembrolizumab was effective for treatment of both 
cancers in each patient.  
 
  
Introduction 
Lung cancer is a major health concern worldwide—with an estimated 1.8 
million new cases globally in 2012 representing 12.9% of all new cancer cases [1, 2]. 
New immunotherapeutic treatments for lung cancer that exploit or protect immune 
surveillance have shown great promise. The immune system can recognize and destroy 
tumors, but can be prevented from doing so by programmed death ligand-1 (PD-L1) 
that is expressed on tumor cells. PD-L1 binds to programmed death-1 (PD-1) on 
cytotoxic T cells to inhibit their activity and up to 68% of non-small cell lung cancer 
(NSCLC) cases reportedly express PD-L1 [3-6]. In 2014, the Food and Drug 
Administration (FDA) approved pembrolizumab, a therapeutic antibody that blocks 
lymphocytic PD-1, for the treatment of advanced NSCLC. However, there is currently 
no standard treatment for double cancer (which is usually diagnosed in older people) as 
it is difficult to perform a large-scale study. As various treatment modalities are being 
developed, the prognosis of many severe cancers (including lung cancer) is improving 
and FDA approval (May 2017) of pembrolizumab as a first-line treatment for any solid 
tumor with certain genetic features has contributed to that improvement. 
Here, we report 2 cases of double cancer involving NSCLC in which 
pembrolizumab was effective for treatment of both cancers. In Case 1, during lung 
cancer treatment, symptoms related to another solid tumor progressed. In Case 2, during 
gastric cancer treatment, symptoms due to lung cancer progression were observed. 
 
Case presentation  
Case 1 
An 83-year-old man presented with an abnormal opacity on chest radiography 
during a health check. He had a 63 pack-year history of smoking and a history of 
cerebellar infarction, diabetes, and lumbar disc herniation. No obvious family history 
for cancer was found. Chest CT revealed a 33-mm mass at the S3 region of the left lung 
and the subaortic lymph node was swollen (24 mm). Bronchoscopic lung biopsy was 
performed and he was diagnosed with stage IIIA squamous cell carcinoma 
(cT2aN2M0). Because evidence for chemoradiotherapy is poor for people over the age 
of 80, chemotherapy alone was performed with 4 cycles of carboplatin in addition to 
paclitaxel. Evaluation at the end of the fourth course showed that the disease remained 
progressive but the patient and his family requested a second-line treatment other than 
cytotoxic anticancer drugs. PD-1 inhibitors have demonstrated durable clinical 
responses in patients with lung squamous cell carcinoma; therefore, Nivolumab, the 
only immune-checkpoint inhibitor available in Japan at that time, was adopted as a 
second-line treatment. By the end of the second course of nivolumab treatment, rapid 
shrinking of the lung tumor was observed. At the end of the fifth course of nivolumab, 
however, the patient was hospitalized for general malaise and an increase in 
inflammatory response. After hospitalization, no evidence of regrowth of the lung tumor 
was found, however, the patient exhibited hematuria. Whole-body computed 
tomographic examination found a protruding tumor in the bladder—a finding consistent 
with the presence of bladder cancer. Urothelial carcinoma was diagnosed with cytology. 
As the examined lung tissue was 70% positive for PD-L1 expression, pembrolizumab 
was selected as a third-line therapy. Interestingly, there is also evidence suggesting that 
pembrolizumab may be effective for urological cancer [7]. After pembrolizumab 
treatment, the macroscopic hematuria was almost fully resolved. The patient is currently 
receiving a thirteenth course of pembrolizumab without major side effects. The lung 
tumor has not increased in size and bladder cancer progression has not been observed 
(Figure 1, 2). 
 
Case 2 
A 78-year-old man with a history of diabetes and hypertension who had 
received oxaliplatin in addition to S-1 treatment for stage IV gastric cancer was 
examined in our hospital. During the course of chemotherapy for gastric cancer, a small 
nodule (5 mm) at the S3 region of the left lung was found on chest CT. Although the 
gastric cancer and the intraperitoneal lymph node showed good response to the 
chemotherapy, the lung tumor gradually increased to 31 × 25 mm in size with 
enlargement of a mediastinal lymph node and a right adrenal gland tumor. The lung 
tumor was diagnosed as stage IVB (cT4N2M1b) squamous cell carcinoma. Obstruction 
in the left main lung bronchus occurred due to the increasing size of the left lung tumor 
and the patient’s general condition showed deterioration (ECOG status 2). While 
waiting for the results of PD-L1 expression testing, chemotherapy with carboplatin in 
addition to nab-paclitaxel (adjusted for lung and gastric cancer) was administered. 
However, on day 6, pneumonia-triggered septic shock occurred for which noradrenaline 
was administered, making continuation of the chemotherapy difficult. As the PD-L1 
expression of the examined lung cancer tissue was 90% positive after 2 weeks, 
pembrolizumab was administered as a second-line treatment. The lung tumor shrank 
rapidly thereafter and the gastric cancer also resolved without recurrence (verified by 
endoscopic examination) (Figures 3 and 4). There were no major side effects and the 
patient is currently receiving a fourth pembrolizumab course. 
 
Discussion 
We have introduced 2 cases of double cancer that showed good response to 
pembrolizumab. In the first case, the lung cancer was successfully treated with another 
immune checkpoint inhibitor, but the comorbid bladder cancer progressed, and the 
patient’s general condition worsened. In the second case, the treatment of the gastric 
cancer was efficacious with another cytotoxic agent, but the lung cancer progressed, and 
the patient’s general condition worsened. The findings of these 2 cases might appear 
contradictory, but in such cases of double cancer in elderly people, the initially 
diagnosed cancer is more likely than the second cancer to be treated effectively. 
Although lung cancer treatment is developing rapidly, the increasing complexity of 
multiple metastases, genetic components, and comorbidities confound standardization 
of therapy. To this end, it has been proposed that treatments be classified based on 
presence or absence of brain metastasis, since the blood brain barrier, as well as genetic 
mutations could be important complicating factors [8]. 
The KEYNOTE-010 Study (NCT01905657) was a randomized, open-label, 
phase II and III clinical trial comparing the safety and efficacy of pembrolizumab with 
that of docetaxel in patients with PD-L1-expressing NSCLC tumors [9]. Pembrolizumab 
demonstrated an improved overall survival (OS) benefit at both the tested doses in the 
total population compared with docetaxel. Pembrolizumab also had a better safety 
profile than docetaxel, with fewer high-grade adverse effects [9]. Many studies have 
reported the efficacy of pembrolizumab in bladder cancer and, recently, its economic 
effects have also been reported [10-12]. Additionally, as with other immune checkpoint 
inhibitors like nivolumab, the efficacy of pembrolizumab even for gastric cancer cases 
was reported in the KEYNOTE-059 study [13]. Compared to relatively rare cancers 
such as malignant melanoma, simultaneous occurrence of secondary cancer is more 
frequently observed with lung cancer due to the larger number of patients.  
Due to global aging, it is likely that pulmonologists will have to treat 
increasing numbers patients diagnosed with multiple cancers. In the past, for patients 
with lung cancer who developed other uncontrolled cancers, palliative care was the only 
option when the lung cancer did not respond to general anticancer drugs. However, as it 
is now possible to use immune checkpoint inhibitors, which have few side effects and 
are indicated for many solid tumors, more patients with double cancer can be 
successfully treated as in the cases presented here. Recently, attempts have been made 
to combine several target molecules for treatment [14,15]. Lung cancer itself is a 
heterozygous disorder and has been considered difficult to control even when targeting 
a single molecule. However, there is a possibility that such multicarrier targeted 
anticancer drugs combined with checkpoint inhibitors will enable the more effective 
treatment of multiple cancers. In the literature, it seems as if immunity checkpoint 
inhibitors are only compared to cytotoxic anticancer drugs but even in multiple cancers 
we can firmly diagnose the molecular features of cancer by biopsy. This leads to the 
idea that using dual (or multi)-targeted proteins based on individualized molecular 
features might be more effective than blanket antibody or cytotoxic treatments and this 
possibility remains to be fully investigated. 
  Because pembrolizumab requires a pathological assessment via biopsy of the 
lung tumor or its metastatic lesion, these cases have primarily come to the respiratory 
medicine departments of hospitals. However, immune checkpoint inhibitors may be 
used more often for the treatment of multiple cancers in many clinical departments as 
knowledge regarding their indication increases. 
 
Conclusion 
With the rapidly aging global population, diagnoses of double cancer cases are 
increasing and palliative care was, until recently, the only option for many of these 
patients. However, as demonstrated in the 2 cases presented here, innovative new 
treatments for solid tumors (such as immune checkpoint inhibitors like pembrolizumab) 
have opened further avenues to treat lung cancer more effectively, even when it is 
comorbid with other cancers. 
  
Supplementary 
Detailed treatment information case 1 
1st line CBDCA+PTX #1-4 
2nd line Nivolumab #1-5 
3rd line Pembrolizumab #1- 
 
Detailed treatment information case 2 
1st line CBDCA+nabPTX #1 
2nd line Pembrolizumab #1- 
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Figures 
Figure 1 
(a) Chest X-ray before Nivolumab treatment. A tumor can be observed in the left hilar 
area. 
(b) Chest X-ray after the 13th course of Pembrolizumab. The tumor showed a marked 
shrinkage in size. 
 
Figure 2 
(a) Lower abdomen CT after 5 Nivolumab courses. A protruding tumor can be observed 
in the bladder. Because of hematuria, a catheter was placed in the bladder. 
(b) Lower abdomen CT after the end of 13 courses of Pembrolizumab. Macroscopic 
hematuria has disappeared. The bladder mass has remained, but without increase in size. 
 
Figure 3 
(a) Chest X-ray before Pembrolizumab treatment. A tumor can be observed in the left 
hilar area. 
(b) Chest X-ray after the 4th course of Pembrolizuma. The tumor showed a marked 
shrinkage in size. 
 Figure 4 
(a) (b) Gastric fiber findings before any treatment. Blood is accumulated in the stomach. 
A Borrmann type III lesion is recognized on the wall just behind the cardia. Bleeding 
continues from the ulcer. A biopsy was conducted from the surrounding embankment, 
which confirmed gastric cancer. 
(c) Gastric fiber findings after 4 courses of Pembrolizumab. Gastric cancer at the same 
location cannot be confirmed with the camera. (d) Narrow band imaging findings from 
the same site. 
 
 
 
 
